Disclosed herein are compounds of Formula (A) as defined herein, and combinations of compounds, for treating amylodosis. Some of the types of amyloidosis that are treated include amyloid light-chain (AL) amyloidosis, amyloid type A (AA) amyloidosis, dialysis-related amyloidosis (DRA), familial or hereditary amyloidosis, age-related (senile) systemic amyloidosis, and organ-specific amyloidosis. In various embodiments, a compound of the Formula (A) is used in combination with a corticosteroid for the treatment of amyloidosis.

##STR00001##

Compositions and methods for treating viral infection are disclosed. The compositions contain a combination of zinc and a cyclo(His-Pro), in effective amounts. The composition containing a combination of zinc and a cyclo(His-Pro) can be used to treat viral infections including SARS-CoV-2 infections in mammals.

Compositions and methods for treating viral infection are disclosed. The compositions contain a combination of zinc and a cyclo(His-Pro), in effective amounts. The composition containing a combination of zinc and a cyclo(His-Pro) can be used to treat viral infections including SARS-CoV-2 infections in mammals.

As new class of drugs designated systems chemico-pharmacology drugs (SCPD) is disclosed. SCPDs work by targeting a druggable biomolecular site (the first target), resulting in a significant change in the properties of the first target. In the process, the SCPD itself is chemically modified. Subsequently, the resulting modified SCPD interacts with a second target, which is also modified in a manner that is beneficial for the patient.

Compositions and methods for treating glioma and converting glioma cells into neurons are provided. The compositions contain an effective amount of SKL2001, and may also contain one, two, three or four of 0431542, LDN193189, CHIR99021, and DAPT. Pharmaceutical compositions containing SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT are provided. Also provided are articles of manufacture which contain one or more sealed containers that contain SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT, are provided. The articles of manufacture can contain printed material providing an indication that the compound(s) are for use in treating glioma.

Compositions and methods for treating glioma and converting glioma cells into neurons are provided. The compositions contain an effective amount of SKL2001, and may also contain one, two, three or four of 0431542, LDN193189, CHIR99021, and DAPT. Pharmaceutical compositions containing SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT are provided. Also provided are articles of manufacture which contain one or more sealed containers that contain SKL2001 and one, two, three or four of SB431542, LDN193189, CHIR99021, and DAPT, are provided. The articles of manufacture can contain printed material providing an indication that the compound(s) are for use in treating glioma.

The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably L-glutamine; a dipeptide capable of releasing glutamine, L-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine; an oligopeptide consisting of two to seven glutamine, preferably L-glutamine residues; and mixtures thereof. The peritoneal dialysis fluids of the present invention are useful for inhibition of technical failure in a person undergoing peritoneal dialysis treatment.

The present invention relates to a carbohydrate-based peritoneal dialysis fluid, containing a compound selected from the group consisting of glutamine, preferably L-glutamine; a dipeptide capable of releasing glutamine, L-glutamine in free form, preferably selected from the group consisting of glutaminyl-glycine, glycinyl-glutamine, glutaminyl-alanine, alanyl-glutamine; an oligopeptide consisting of two to seven glutamine, preferably L-glutamine residues; and mixtures thereof. The peritoneal dialysis fluids of the present invention are useful for inhibition of technical failure in a person undergoing peritoneal dialysis treatment.

A method is provided for treating a subject for a viral infection. The method includes diagnosing the subject as having a viral infection, and administering a pharmaceutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes a poly-N-substituted glycine compound of a formula AX-Y-Z.sub.n—B, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH.sub.2, one and two N-substituted glycine residues, and wherein said one and two N-substituted glycine residues have N-substituents which are independently selected from natural α-amino acid side chain moieties, isomers and carbon homologs thereof; X, Y and Z are independently selected from the group consisting of N-substituted glycine residues, wherein said N-substituents are independently selected from the group consisting of natural α-amino acid side chain moieties, isomers and carbon homologs thereof, and proline residues. In some embodiments, at least one of A, B, X, Y and Z contains a halogen-bearing moiety.

A method is provided for treating a subject for a viral infection. The method includes diagnosing the subject as having a viral infection, and administering a pharmaceutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes a poly-N-substituted glycine compound of a formula AX-Y-Z.sub.n—B, wherein A is a terminal N-alkyl substituted glycine residue; n is an integer; B is selected from the group consisting of NH.sub.2, one and two N-substituted glycine residues, and wherein said one and two N-substituted glycine residues have N-substituents which are independently selected from natural α-amino acid side chain moieties, isomers and carbon homologs thereof; X, Y and Z are independently selected from the group consisting of N-substituted glycine residues, wherein said N-substituents are independently selected from the group consisting of natural α-amino acid side chain moieties, isomers and carbon homologs thereof, and proline residues. In some embodiments, at least one of A, B, X, Y and Z contains a halogen-bearing moiety.